Effect of Estrogen and testosterone hormones and some biochemical components on male patients of prostatic hyperplasia in Tikrit city.
Article Sidebar
Main Article Content
Abstract
This study had been performed in Tikrit Teaching Hospital and aimed to determine the effects of the men prostatic hyperplasia in the concentrations of prostatic specific antigen (PSA), Acid phosphatase (PAcP) ,Cholesterol. The number of patients and healthy was 60, 40 respectively, ranged patients and healthy reconstruction (47. 90 years old). The patients were diagnosed by medical staff and sonar devices in the hospital above. The results were: patients have high significant concentrations in PSA, PAcP enzyme, cholesterol and estrogen compared with healthy. While healthy have high significant compared with patients in the concentration of testosterone, and has decreased concentrations.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1- Chang IH, Oh SY. And Kim SC. (2009). A possible relationship between testosterone and Lower Urinary Tract Symptoms in men. J. Urol. Jul; 182, 215-20.
2- Mahmood, I. S.; Al-Dohan, J. A. and Salih, M. M. (2013). Effects of sex hormones on prostate voleum in patients with lowerurinary tract symptoms. Bas. J. Surg, September, 19: 15-22.
3- Gjertson CK, Walmsley K, and Kaplan SA. (2004). Benign prostatic hyperplasia: Now we can begin to tailor treatment. Clev Clin J Med;71(11): 857-865.
4- Menon, D. (2007). Photo selective vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH). Alberta heaith technologies decision process. School of Public Health, University.
5- Leao, R.; Pereira, B. J. and Coelho, H. (2012). Benign prostate hyperplasia and chronic kidney disease. Chronic Kidney Disease Edited by Prof. Monika Göőz. ISBN 978-953-51-0171-0 Hard cover, 444 pages.www.intechopen.com.
6- Malati, T. ; Kumari, G. R. ; Murthy, P.V.L.N. ; Reddy, C. R. and Prakash, B. S. (2006). Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Indian Journal of Clinical Biochemistry, 21 (1) 34-40.
7- Moul, JW.; Connelly, RR.; Perahia, B. and McLeod DG. (1998). The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol 1998;159:935-940.
8- Corona, G.; Vignozzi, L.; Rastrelli, G.; Lotti, F.; ipriani. S. and Maggi, M. (2014). Benign prostatic hyperplasia: A new metabolic disease of the aging male and its correlation with sexual dysfunctions. International Journal of Endocrinology. Volume 2014, Article ID 329456, 14 pages. http://dx.doi.org/10.1155/2014/329456.
9- Yat-Ching T. (2011). The role of cholesterol in prostatic diseases. Urological Science 22 : 97-102.
10 الرررر ا رو ، لا رررر محمرررروة م - 2000 ( م مررررةل ىلررررع الإحصررررا م
الاععة ال انية م ةار الكت للاعاعة والن ر جامعة الموص م –
11-Babaian, RJ; Miyashita, H; Evans, RB; Ramirez EI. (1992). The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol;147:837–40 .
12- Muniyan, S.; Chaturvedi, N. K.; Dwyer, J. G.; LaGrange, C. A. ; William G. Chaney, W. G. and Lin, MF. (2013). Human prostatic acid phosphatase: structure, function and regulation . Int. J. Mol. Sci., 14, 10438-10464.
13- Porvari, K.; Kurkela, R.; Kivinen, A.; Vihko, P. (1995). Differential androgen regulation of rat prostatic acid phosphatase transcripts. Biochem. Biophys. Res. Commun., 213, 861–868 .
14- Zelivianski, S.; Comeau, D.; Lin, M.F. (1998). Cloning and analysis of the promoter activity of the human prostatic acid phosphatase gene. Biochem. Biophys. Res. Comm, 245, 108–112.
15- Solin, T.; Kontturi, M.; Pohlmann, R.; Vihko, P. (1990). Gene expression and prostate specificity of
ISSN:1813 – 1662 2015 ) 1( مجلة تكريت للعلوم الصرفة، 20
19
human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses. Biochim. Biophys.Acta, 1048, 72–77.
16- Vikram, A. and Ramarao, P ( 2012). Lipids in the pathogenesis of benign prostatic hyperplasia: emerging connections. Dyslipidemia – From Prevention to Treatment . 411-426 .
17- McKeehan, W.L., Adams, P.S., Rosser, M.P., (1984). Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res, 44, 1998-2010.
18- Cai, X., Haleem, R., Oram, S., Cyriac, J., Jiang, F., Grayhack, J.T.,. Kozlowski, J.M., Wang, Z., 2001. High fat diet increases the weight of rat ventral prostate. Prostate, 49, 1-8.
19- Ikeda, K., Wada, Y., Foster, H.E., Jr., Wang, Z., Weiss, R.M., Latifpour, J. ,( 2000). Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-beta. J Urol, 164, 180-185.
20- Nicholson, TM; Ricke, WA. (2011). Androgens and estrogens in benign prostatic hyperplasia: Past, present and future. Differentiation 2011; 82:184-99.
21- Prins, GS; Korach, KS. (2008). The role of estrogens and estrogen receptors in normal prostate growth and disease. steroids; 73:233-44.
22- Dillner, K.(2003). Molecular Characterization of Prostate Hyperplasia in Prolactin Transgenic Mice. Thesis Department of Physiology and Pharmacology Sahlgrenska Academy, Göteborgs University Sweden.
23- Prezioso, D.; Denis, L. J.; Klocker, H.; Sciarra, A.; Reis, M.; Kur Naber, K.; Lobel, B.; Dalibor Pacik, D. and Griffiths, k. (2007). Estrogens and aspects of prostate disease. International Journal of Urology (2007) 14, 1–16.
24- Mcpherson, S. J.; Wang, H.; Jones, M. E.; Pedersen, J. ; Iismaa, T. P.; Wreford, N. ; Even R. ; Simpson, E. R. and Risbridger, G. P. (2001). Elevated androgens and Prolactin in aromatase deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 142, (6) : 2458 – 2467.
25- Ellem, S.J. Wang,. H. Poutanen,. M.. Risbridger, G.P. (2009) Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy, Am. J. Pathol. 175 (3) 1187–1199.
26- James B. M. ; Beth M. ; Michael, J. B. ; Mary Mc. C. ; John B. Mc. (2001). Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. Journal of Clinical Epidemiology 54 : 935–944 .
27- Kolota, G. (2004). "It was medical gospel, but It wasn't true". The New York Times: p. 47.
28- Banas, B.; Blaschke, D.; Fittler, F.; Horz, W. (1994). Analysis of the promoter of the human prostatic acid phosphatase gene. Biochim. Biophys. Acta, 1217, 188–194.
29- Tong, Y. (2011). The role of cholesterol in prostatic diseases . Urological Science 22 : 97-102 .
30- Zeng, QS; Xu, CL; Liu ,ZY, et al. ( 2012) . Relationship between serum sex hormones levels and degree of benign prostate hyperplasia in Chinese aging men. Asian J Androl Sep; 14(5):773-7.
31- Montie, JEA and Pienta ,LJA. (1994). Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology Jun; 43(6):892-9.
32- Richard K. D. Ephraim1*, Deric Baah-Asinor1, Derick N. M. Osakunor2, Billy Osei-Acheampong3, Emmanuel Diabor1, Justice Afrifa1 and David L. Simpong. (2014). Effects of Body Mass Index and Age on Prostate Specific Antigen: A Study on Men Attending a Tertiary Hospital in Ghana. British Journal of Medicine & Medical Research 4(18): 3519-3528.
33- Imamoto, T.; H Suzuki,; Yano, M.; Kawamura, K.; Kamiya, N.; Araki, K.; Komiya, A.; Naya, Y.; T Shiraishi, T. and Ichikawa, T. (2009). Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?. Prostate Cancer and Prostatic Diseases, 12:78–82.
34- Lee, S.: Min, H. G.; Choi, S. H.; Kim, Y. J.; Oh, S. W.; Young Joo Kim, Y. J.; Park, Y. and Kim, S. S. (2006). Central obesity as a risk factor for prostatic hyperplasia. OBESITY Vol. 14 (1(: 172-179.
35- Mosli, H. A. and Mosli, H. H. (2013). Influence of body mass index on Benign Prostatic Hyperplasia-related complications in patients undergoing prostatectomy .SpringerPlus 2013, 2:537 http://www.springerplus.com/content/2/1/537.
36- Collins, AT; Zhiming , B; Gilmore, K ; Neal DE. (1994). Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: oestrogen regulation of the androgen receptor. J Endocrinol Nov; 143:269-77.